Search - tctmd.com

Displaying 301 - 320 of 413

Sort: Relevancy | Date

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

February 04, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

Presentation

Reduction in Total CV Events With Ezetimibe-Simvastatin Post-ACS: IMPROVE-IT

Presenter: SA. Murphy

January 25, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

Michael O'Riordan

January 17, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Michael O'Riordan

December 20, 2015

News Daily News

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Michael O'Riordan

December 20, 2015

Advertisement

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

TCTMD’s Top 10 Most Popular Stories for January 2016

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Reduction in Total CV Events With Ezetimibe-Simvastatin Post-ACS: IMPROVE-IT

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content